These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 27974457)

  • 1. Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.
    Li R; Rezk A; Ghadiri M; Luessi F; Zipp F; Li H; Giacomini PS; Antel J; Bar-Or A
    J Immunol; 2017 Jan; 198(2):691-698. PubMed ID: 27974457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
    Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
    Front Immunol; 2018; 9():1097. PubMed ID: 29896193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dimethyl Fumarate Selectively Reduces Memory T Cells and Shifts the Balance between Th1/Th17 and Th2 in Multiple Sclerosis Patients.
    Wu Q; Wang Q; Mao G; Dowling CA; Lundy SK; Mao-Draayer Y
    J Immunol; 2017 Apr; 198(8):3069-3080. PubMed ID: 28258191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dimethyl fumarate induces changes in B- and T-lymphocyte function independent of the effects on absolute lymphocyte count.
    Longbrake EE; Cantoni C; Chahin S; Cignarella F; Cross AH; Piccio L
    Mult Scler; 2018 May; 24(6):728-738. PubMed ID: 28480794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile.
    Medina S; Villarrubia N; Sainz de la Maza S; Lifante J; Costa-Frossard L; Roldán E; Picón C; Álvarez-Cermeño JC; Villar LM
    Mult Scler; 2018 Sep; 24(10):1317-1327. PubMed ID: 28653862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice.
    Mehta D; Miller C; Arnold DL; Bame E; Bar-Or A; Gold R; Hanna J; Kappos L; Liu S; Matta A; Phillips JT; Robertson D; von Hehn CA; Campbell J; Spach K; Yang L; Fox RJ
    Neurology; 2019 Apr; 92(15):e1724-e1738. PubMed ID: 30918100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis.
    Yadav SK; Soin D; Ito K; Dhib-Jalbut S
    J Mol Med (Berl); 2019 Apr; 97(4):463-472. PubMed ID: 30820593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dimethyl fumarate promotes B cell-mediated anti-inflammatory cytokine profile in B and T cells, and inhibits immune cell migration in patients with MS.
    Najjar E; Staun-Ram E; Volkowich A; Miller A
    J Neuroimmunol; 2020 Jun; 343():577230. PubMed ID: 32247228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes.
    Carlström KE; Ewing E; Granqvist M; Gyllenberg A; Aeinehband S; Enoksson SL; Checa A; Badam TVS; Huang J; Gomez-Cabrero D; Gustafsson M; Al Nimer F; Wheelock CE; Kockum I; Olsson T; Jagodic M; Piehl F
    Nat Commun; 2019 Jul; 10(1):3081. PubMed ID: 31300673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis.
    Traub J; Traffehn S; Ochs J; Häusser-Kinzel S; Stephan S; Scannevin R; Brück W; Metz I; Weber MS
    Brain Pathol; 2019 Sep; 29(5):640-657. PubMed ID: 30706542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
    Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
    J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
    Naismith RT; Wundes A; Ziemssen T; Jasinska E; Freedman MS; Lembo AJ; Selmaj K; Bidollari I; Chen H; Hanna J; Leigh-Pemberton R; Lopez-Bresnahan M; Lyons J; Miller C; Rezendes D; Wolinsky JS;
    CNS Drugs; 2020 Feb; 34(2):185-196. PubMed ID: 31953790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis.
    Diebold M; Sievers C; Bantug G; Sanderson N; Kappos L; Kuhle J; Lindberg RLP; Derfuss T
    J Autoimmun; 2018 Jan; 86():39-50. PubMed ID: 28958667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
    Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
    Clin Ther; 2014 Dec; 36(12):1958-1971. PubMed ID: 25315404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.
    Fleischer V; Friedrich M; Rezk A; Bühler U; Witsch E; Uphaus T; Bittner S; Groppa S; Tackenberg B; Bar-Or A; Zipp F; Luessi F
    Mult Scler; 2018 Apr; 24(5):632-641. PubMed ID: 28436295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
    Su W; Kansal A; Vicente C; Deniz B; Sarda S
    J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
    Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
    Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis.
    Holm Hansen R; Højsgaard Chow H; Sellebjerg F; Rode von Essen M
    Mult Scler; 2019 Aug; 25(9):1289-1297. PubMed ID: 30043661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients.
    Montes Diaz G; Fraussen J; Van Wijmeersch B; Hupperts R; Somers V
    Sci Rep; 2018 May; 8(1):8194. PubMed ID: 29844361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.